Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Stomatovis** is a D.M.G. Italia oral mucosal-protection medical device supplied as a mouthwash/gargle. It is intended to prevent and treat symptoms associated with stomatitis and gingivitis of different origins and to lubricate and hydrate the oral mucosa. Its formulation includes mucosal-protective and film-forming components such as marshmallow mucilage, dipotassium glycyrrhizinate, carboxymethyl beta-glucan, phosphoglucan, PVM/MA copolymer, xylitol, glycerol, and sodium bicarbonate. It does not have a single defined pharmacologic active ingredient or molecular target; its intended effect is primarily local physical mucosal protection, lubrication, and hydration. In a randomized controlled study in adults undergoing elective genitourinary surgery with orotracheal intubation, Stomatovis gargle showed a modest but non-statistically-significant reduction in postoperative sore throat relative to control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stomatovis.